Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood

Executive Summary

• Biomind Labs announced that its BMND08 program is moving into FDA‑directed, commercial‑stage activities using a newly engineered nano‑formulation delivery platform.
• The company reported successful resolution of third‑party patent observations, strengthening its IP position for the nano‑technology.
• An aggregate 6,200,000 incentive stock options were granted to directors, officers and consultants at an exercise price of $0.35 per share, expiring November 3 2030.

Key Details

• Regulatory Milestone: BMND08 transitions from Phase 2 to FDA‑directed commercial pathway; company will prepare a nano‑formulation package for the FDA, discuss pivotal trial design and seek eligibility for expedited programs (e.g., Breakthrough Therapy).
• Clinical Background: Phase 2 trial achieved a 100% response rate in Alzheimer’s‑related mood disorders, establishing a new benchmark.
• Nano‑Formulation Benefits: Claims of superior dosing precision, safety, absorption, and scalability for commercial‑stage trials in neuropsychiatric and neurodegenerative indications.
• Intellectual Property Update: All third‑party patent observations filed with the patent office have been resolved; the related patent application remains in good standing, reinforcing novelty and defensibility of the nano‑technology.
• Equity Incentive Grant: 6,200,000 incentive stock options granted to certain directors, officers, and consultants; exercise price $0.35 per share; expiration date November 3 2030.
• Future Plans: Company will prepare regulatory and technical prerequisites for FDA submission, define pivotal trial design, and evaluate eligibility for expedited regulatory programs.

Notable Quotes

“Advancing BMND08 into the FDA's commercial pathway using our proprietary nano‑formulation is a transformative moment for the Company.” – Alejandro Antalich, CEO, Biomind Labs Inc.